脑胶质瘤免疫治疗进展

doi:10.3969/j.issn.1006-7795.2019.06.028

摘要/Abstract

摘要： 脑胶质瘤是中枢神经系统最常见的原发性脑肿瘤类型，也是最具破坏性的肿瘤之一。经手术治疗、放射治疗及化学药物治疗等综合治疗后，其生存期仍然很短。近年来癌症免疫治疗方法在治疗实体肿瘤中取得巨大成功，然而在脑胶质瘤治疗中的应用尚不普遍。本文就脑胶质瘤的免疫治疗以及研究进展进行综述。

关键词: 胶质瘤, 免疫检查点抑制剂, 嵌合抗原受体T细胞治疗, 绿原酸, 溶瘤病毒

Abstract: Gliomas are the most common type of primary brain tumors in the central nervous system and one of the most devastating tumors. After surgery,radiotherapy and chemotherapy,the overall survival is still very short. In recent years,cancer immunotherapy has achieved significant success in the treatment of solid tumors,however,its use in gliomas is not universal. This review discussed the immunotherapy and latest progress in glioma study.

Key words: glioma, immune checkpiont inhibitors, chimeric antigen receptor T-cell therapy, chlorogenic acid, oncolytic virus

中图分类号:

R739.41

陈峰, 郑晓红, 李文斌. 脑胶质瘤免疫治疗进展[J]. 首都医科大学学报, 2019, 40(6): 966-971.

Chen Feng, Zheng Xiaohong, Li Wenbin. Immunotherapy for the treatment of glioma[J]. Journal of Capital Medical University, 2019, 40(6): 966-971.

参考文献

[1] Xue S,Hu M,Iyer V,et al. Blocking the PD-1/PD-L1 pathway in glioma:a potential new treatment strategy[J]. J Hematol Oncol,2017,10(1):81.
[2] Louis D N,Perry A,Reifenberger G,et al. The 2016 World Health Organization Classification of tumors of the central nervous system:a summary[J]. Acta Neuropathol,2016,131(6):803-820.
[3] Stupp R, Hegi M E, Mason W P, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase Ⅲ study:5-year analysis of the EORTC-NCIC trial[J]. Lancet Oncol, 2009, 10(5):459-466.
[4] Goel G, Sun W. Cancer immunotherapy in clinical practice-the past,present,and future[J]. Chin J Cancer,2014,33(9):445-457.
[5] John L B,Devaud C,Duong C P,et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells[J]. Clin Cancer Res,2013,19(20):5636-5646.
[6] Tanaka Y, Okamura H. Anti-PD-1 antibody:basics and clinical application[J]. Gan To Kagaku Ryoho,2013,40(9):1145-1149.
[7] 王镔, 赵刚. 脑胶质瘤免疫治疗的进展与展望[J]. 中国微侵袭神经外科杂志,2018,23(11):523-526.
[8] Specenier P. Ipilimumab in melanoma[J]. Expert Rev Anticancer Ther,2016,16(8):811-826.
[9] Kohnke T,Krupka C,Tischer J,et al. Increase of PD-L1 expressing B-precursor all cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab[J]. J Hematol Oncol,2015,8:111.
[10] Simonelli M,Persico P,Perrino M,et al. Checkpoint inhibitors as treatment for malignant gliomas:"A long way to the top"[J]. Cancer Treat Rev,2018,69:121-131.
[11] Weber J S,Kudchadkar R R,Yu B,et al. Safety,efficacy,and biomarkers of nivolumab with vaccine in ipilimumab-refractory or-naive melanoma[J]. J Clin Oncol,2013,31(34):4311-4318.
[12] Hamid O,Robert C,Daud A,et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma[J]. N Engl J Med,2013,369(2):134-144.
[13] Balar A V, Weber J S. PD-1 and PD-L1 antibodies in cancer:current status and future directions[J]. Cancer Immunol Immunother,2017,66(5):551-564.
[14] Nduom E K,Wei J,Yaghi N K,et al. PD-L1 expression and prognostic impact in glioblastoma[J]. Neuro Oncol,2016,18(2):195-205.
[15] Omuro A,Vlahovic G,Lim M,et al. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma:results from exploratory phase I cohorts of CheckMate 143[J]. Neuro Oncol,2018,20(5):674-686.
[16] Filley A C, Henriquez M. Recurrent glioma clinical trial,CheckMate-143_the game is not over yet[J]. Oncotarget,2017,8(53):91779-91794.
[17] Lyon J G,Mokarram N,Saxena T,et al. Engineering challenges for brain tumor immunotherapy[J]. Adv Drug Deliv Rev,2017,114:19-32.
[18] Dai H,Wang Y,Lu X,et al. Chimeric antigen receptors modified T-cells for cancer therapy[J]. J Natl Cancer Inst,2016,108(7):pii.
[19] Grupp S A,Kalos M,Barrett D,et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia[J]. N Engl J Med,2013,368(16):1509-1518.
[20] Schuster S J,Svoboda J,Chong E A,et al. Chimeric antigen receptor T cells in refractory B-Cell lymphomas[J]. N Engl J Med,2017,377(26):2545-2554.
[21] Ali S A,Shi V,Maric I,et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma[J]. Blood,2016,128(13):1688-1700.
[22] Dudley M E,Yang J C,Sherry R,et al. Adoptive cell therapy for patients with metastatic melanoma:evaluation of intensive myeloablative chemoradiation preparative regimens[J]. J Clin Oncol,2008,26(32):5233-5239.
[23] Posey A D,Jr.,Schwab R D,Boesteanu A C,et al. Engineered CAR T cells targeting the cancer-associated Tn-Glycoform of the membrane mucin MUC1 control adenocarcinoma[J]. Immunity,2016,44(6):1444-1454.
[24] Heckler M, Dougan S K. Unmasking pancreatic cancer:epitope spreading after single antigen chimeric antigen receptor T-Cell therapy in a human phase I trial[J]. Gastroenterology,2018,155(1):11-14.
[25] Wei X,Lai Y,Li J,et al. PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells[J]. Oncoimmunology,2017,6(3):e1284722.
[26] Brown C E,Badie B,Barish M E,et al. Bioactivity and safety of IL13 Rα2-redirected chimeric antigen receptor CD8⁺ T cells in patients with recurrent glioblastoma[J]. Clin Cancer Res,2015,21(18):4062-4072.
[27] Brown C E,Alizadeh D,Starr R,et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy[J]. N Engl J Med,2016,375(26):2561-2569.
[28] O'Rourke D M,Nasrallah M P,Desai A,et al. A single dose of peripherally infused EGFRvⅢ-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma[J]. Sci Transl Med,2017,9(399):pii.
[29] Ahmed N,Brawley V,Hegde M,et al. HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma:a phase 1 dose-escalation trial[J]. JAMA Oncol,2017,3(8):1094-1101.
[30] Jin L,Ge H,Long Y,et al. CD70,a novel target of CAR T-cell therapy for gliomas[J]. Neuro Oncol,2018,20(1):55-65.
[31] Mount C W,Majzner R G,Sundaresh S,et al. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M(+) diffuse midline gliomas[J]. Nat Med,2018,24(5):572-579.
[32] Chow K K,Naik S,Kakarla S,et al. T cells redirected to EphA2 for the immunotherapy of glioblastoma[J]. Mol Ther,2013,21(3):629-637.
[33] Wang F,Shang Z,Xu L,et al. Profiling and identification of chlorogenic acid metabolites in rats by ultra-high-performance liquid chromatography coupled with linear ion trap-Orbitrap mass spectrometer[J]. Xenobiotica,2018,48(6):605-617.
[34] Xue N,Zhou Q,Ji M,et al. Chlorogenic acid inhibits glioblastoma growth through repolarizating macrophage from M2 to M1 phenotype[J]. Sci Rep,2017,7:39011.
[35] Sitarek P,Skala E,Toma M,et al. A preliminary study of apoptosis induction in glioma cells via alteration of the Bax/Bcl-2-p53 axis by transformed and non-transformed root extracts of Leonurus sibiricus L[J]. Tumour Biol,2016,37(7):8753-8764.
[36] Belkaid A,Currie J C,Desgagnes J,et al. The chemopreventive properties of chlorogenic acid reveal a potential new role for the microsomal glucose-6-phosphate translocase in brain tumor progression[J]. Cancer Cell Int,2006,6:7.
[37] Park J J,Hwang S J,Park J H,et al. Chlorogenic acid inhibits hypoxia-induced angiogenesis via down-regulation of the HIF-1alpha/AKT pathway[J]. Cell Oncol (Dordr),2015,38(2):111-118.
[38] Ezzeddine Z D,Martuza R L,Platika D,et al. Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene[J]. New Biol,1991,3(6):608-614.
[39] van den Bossche W B L,Kleijn A,Teunissen C E,et al. Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment[J]. Neuro Oncol,2018,20(11):1494-1504.
[40] Desjardins A,Gromeier M,Herndon J E,et al. Recurrent glioblastoma treated with recombinant poliovirus[J]. N Engl J Med,2018,379(2):150-161.
[41] Idema S,Lamfers M L,van Beusechem V W,et al. AdDelta24 and the p53-expressing variant AdDelta24-p53 achieve potent anti-tumor activity in glioma when combined with radiotherapy[J]. J Gene Med,2007,9(12):1046-1056.